Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocuvers-L
- Development stage
- Unknown
- Lead developer
- Innomedis
- Administration
- Topical, Ophthalmic
01
Overview
Ocuvers-L is a low-concentration phospholipid-based ophthalmic eye spray developed by innomedis AG for the treatment of dry eye disease and disorders of the lacrimal system. As a medical device, it is formulated as a liposomal spray containing soy lecithin and is applied to closed eyelids. The liposomes migrate to the eyelid margin and supplement the lipid layer of the tear film upon blinking, which improves tear film stability (measured by non-invasive break-up time, NIBUT) and reduces evaporation. The formulation is free of ethanol and benzalkonium chloride, making it odorless and suitable for sensitive eyes.
- Brand names
- ocuvers spray lipostamin
- Other names
- ocuversocuvers spray lipostamin L
Beyond the preview
Go deeper on Ocuvers-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocuvers-L.